World Latest on global search for coronavirus vaccine: Three candidates show early promise

05:41  23 may  2020
05:41  23 may  2020 Source:   usatoday.com

Trump to tap ex-Glaxo exec, U.S. general for coronavirus vaccine effort

  Trump to tap ex-Glaxo exec, U.S. general for coronavirus vaccine effort Trump to tap ex-Glaxo exec, U.S. general for coronavirus vaccine effortThe former head of Glaxo's vaccines division, Moncef Slaoui, will serve as chief adviser on the operation and U.S. General Gustav Perna will act as its chief operating officer. Trump previously said he would be the top boss on the effort to develop, test and produce on a shortened timeline a vaccine against the deadly coronavirus that has caused a global pandemic.

WASHINGTON — A global arms race for a coronavirus vaccine is underway. In the three months since the virus began its deadly spread, China In the past two months, the coalition has funded research into eight of the most promising candidates to block the coronavirus — including CureVac

Moderna has revealed some promising findings on its coronavirus vaccine candidate . The company said Monday that during the phase one trial of its Moderna is moving into phase two of its clinical trials, having received approval from the Food and Drug Administration, and it says the third phase is

An all-out global race to develop a safe vaccine against coronavirus is underway. The stakes couldn't be higher: an effective vaccine or treatment against the virus that causes COVID-19 is necessary to fully restart economies and resume civic life.

As the pace accelerates, USA TODAY is rounding up some of the week's most notable vaccine developments.

U.S. to stockpile vaccine candidates as trials continue -health secretary

  U.S. to stockpile vaccine candidates as trials continue -health secretary The U.S. government plans to stockpile hundreds of millions of doses of vaccines that are under development to combat the novel coronavirus with the goal of having one or more vaccines ready to deploy by the end of the year, the health secretary said on Friday. "We've got over 100 vaccine candidates that have been discovered," Health and Human Services Secretary Alex Azar told Fox Business Network.

In early Phase 1 trial data released Monday, the vaccine was seen to trigger antibody responses in eight healthy volunteers and found to be “generally safe and well-tolerated.” Moderna Analyst Says Coronavirus Vaccine Candidate Has 65% Chance Of Success. See more from Benzinga.

Three potential COVID-19 vaccines are making fast progress in early -stage testing in volunteers in China and America, but it’s still a Coronavirus : what you need to know. China’s CanSino Biologics is beginning the second phase of testing its vaccine candidate , China’s Ministry of Science

They include a massive contract by the U.S. government to get dibs on a possible vaccine that may or may not work, very early but promising news on two different vaccine candidates, one from China and one from the United States, and a caution that sometimes biology can't be sped up as much as we might want.

Start the day smarter. Get all the news you need in your inbox each morning.

A vaccine could work, which we didn't know before

Given all the discussion of a coronavirus vaccine in the news, it can be difficult to remember a crucial fact was missing — whether people who have recovered from COVID-19 were immune to getting it again.

If protective immunity was possible, a vaccine was also likely possible. Until this week that hadn’t been established, even in animals. 

Google Maps helps healthcare workers find hotels

  Google Maps helps healthcare workers find hotels As healthcare professionals continue to battle the coronavirus pandemic across the US and much of the world, Google is adding a new Maps feature to help those individuals find special accommodations when they're done their daily shifts. Starting today, first responders can use the app to find hotels that have special policies in place to help them by typing in a search term like "hotels for essential workers in New York." Another option is toAnother option is to use a less specific phrase like "hotels in New York," and then apply the new "COVID-19 responder rooms" filter Google has added to Maps. The same functionality is also available through the company's search engine.

Could any of these drugs hold the key to saving coronavirus disease 2019 (COVID-19) patients from serious harm or death? On Friday, the World Health Organization (WHO) announced a large global trial, called SOLIDARITY, to find out whether any can treat infections with the new coronavirus for

An early -stage trial of a coronavirus vaccine , published in The Lancet, was conducted by As for the Chinese economy, it shrank in the first three months of the year compared with a year earlier — the In late January, as the coronavirus outbreak spread in China, elementary schools were closed, but

Now it has been. A study at Beth Israel Deaconess Medical Center in Boston published in the journal Science on Wednesday found that nine rhesus macaque monkeys which had recovered from COVID-19 developed natural protective immunity against re-infection with the virus.

Not all viruses generate natural protective immunity, so scientists had worried people could potentially be infected over and over again. The monkey data makes that seem less likely. 

“Our findings increase optimism that the development of COVID-19 vaccines will be possible,” said the study’s leader, Dr. Dan Barouch, a virologist who is also a professor of medicine at Harvard Medical School.

Chinese vaccine shows early promise

Chinese researchers on Friday published a study in the British medical journal The Lancet on an early candidate vaccine tested on 108 healthy adults in Wuhan, China. 

Global COVID-19 cases reach 5 million

  Global COVID-19 cases reach 5 million Here are the latest coronavirus updates from around the world.By Thursday night that number had passed 5.1 million, according to the university.

Latest Updates: Global Coronavirus Outbreak. Sarah Gilbert, 58, modified the same chimpanzee virus to make a vaccine against an earlier coronavirus , MERS. After a clinical trial in Britain demonstrated its safety, another test began in December in Saudi Arabia, where outbreaks of the

Candidate vaccines may be added to the Solidarity trial as they become available if priority criteria are met, while vaccine candidates showing poor evidence The WHO and CEPI are developing financial resources and guidelines for global deployment of three or more safe, effective COVID-19 vaccines

Within two weeks of getting the vaccine, the immune systems of people receiving all three doses showed some level of response, with most developing a type of antibody that can attach to the virus, though not necessarily destroy it. Some also developed so-called neutralizing antibodies, which can kill the virus. 

The vaccine is from CanSino Biologics in Tianjin, China. The trial is in the early stages and it is not yet known if the possible vaccine can generate enough of these neutralizing antibodies to protect people against the virus.

The candidate vaccine is scheduled to be tested in Canada soon. The Canadian Center for Vaccinology is working with CanSino and Canada’s National Research Council to coordinate the trial. Canadian Prime Minister Justin Trudeau made the announcement during a press briefing.

CanSino chairman Xuefeng Yu worked in Canada from 1996 to 2009.

$1.2 billion for first dibs on untried vaccine

On Thursday the United States has pledged to pay as much as $1.2 billion to get early access to 300 million doses of an experimental COVID-19 vaccine being developed and tested in England by the University of Oxford’s Jenner Institute and licensed to British drugmaker AstraZeneca.

Covid-19: The British laboratory AstraZeneca thinks it can produce a billion vaccines

 Covid-19: The British laboratory AstraZeneca thinks it can produce a billion vaccines © Dado Ruvic Vaccine samples The British laboratory AstraZeneca thinks it will be able to supply a billion doses of a potential vaccine against Covid-19, this year and next year. AstraZeneca expects to be able to supply a billion doses of a potential COVID-19 vaccine this year and next year if trials are successful, and the British laboratory said on Thursday it had obtained more than a billion US administration dollars for this research.

A global fight over vaccine doses may erupt. “ Vaccines and international politics have always been tied together. “If the global race over the past few weeks and months to procure coronavirus -related medical equipment is anything to go by … then the competition to acquire precious quantities of a new

Many companies and institutions are in a race to develop a coronavirus vaccine . The Chinese company CanSino Biologics has become the first contender to move its candidate vaccine – Ad5-nCoV – into a phase two clinical trial, which is taking place in Wuhan.

It is expected to be delivered as early as October, though that means only that the doses will be stored until the vaccine completes clinical trials ensuring it is safe and effective in protecting against COVID-19 infection. If it isn't, they'll be destroyed. 

Slideshow by photo services

The vaccine is still in very early clinical trials in humans and is being tested for safety, whether it produces antibodies against SARS-CoV-2, the virus that causes COVID-19, and whether it protects the immunized from becoming infected with the virus. The first tests began in England on April 23.

Merck leaps into COVID-19 development fray with vaccine, drug deals

  Merck leaps into COVID-19 development fray with vaccine, drug deals Merck & Co Inc, which has largely kept to the sidelines of the race for COVID-19 treatments, said it was buying Austrian vaccine maker Themis Bioscience and would collaborate with research nonprofit IAVI to develop two separate vaccines. © REUTERS/Brendan McDermid It also announced a partnership with privately held Ridgeback Biotherapeutics to develop an experimental oral antiviral drug against COVID-19, the respiratory disease caused by the novel coronavirus.It did not disclose the terms of the acquisition of Themis, a privately held company.Merck shares rose more than 3% in premarket trading.

Last week Oxford reported that a single dose of the vaccine caused six rhesus macaque monkeys to develop antibodies to coronavirus within 28 days but did not protect them from becoming infected with COVID-19.

The vaccine, called ChAdOx1, did prevent them from developing pneumonia and lung inflammatory disease when the animals were exposed to the virus.

Moderna vaccine appears safe 

On Monday, Moderna announced its candidate vaccine appeared to be safe when given to eight humans and that it stimulated an immune response to SARS-CoV-2, the virus that causes COVID-19. Experts called it a "so far, so good" finding.

Participants in Phase 1 clinical trial tests made neutralizing antibodies to the virus. When tested on human cells in the laboratory the antibodies stopped the virus from reproducing. 

After two doses of the candidate vaccine, participants' antibody levels were about the same as in people who have recovered from a COVID-19 infection.

There is no data yet on whether the candidate vaccine protects against becoming infected with SARS-CoV-2.

Slow is fast when it comes to vaccines

An editorial in the respected journal Science cautioned against the effort to speed up testing of potential SARS-CoV-2 vaccines. SARS-CoV-2 is the virus that causes COVID-19.

While many advocates have suggested fast-tracking vaccine trials in humans, deputy editor Douglas Green says while clinical trials, especially the large-scale Phase III portion, are time-consuming, they are vital to ensuring a vaccine is safe and effective.

All the vaccine candidates that have been in the news so far are in Phase 1 and Phase 2, meant to test that the vaccine itself doesn't cause reactions and that it causes the body to mount an immune response.

Moving too fast on Phase 3 could be "catastrophic," Green wrote. There are examples of preliminary vaccines that produced neutralizing antibodies but when large trials were conducted they made infections worse.

That happened in a 1966 trial of a vaccine against Respiratory Syncytial Virus, RVS. Subjects who got the vaccine actually did worse when infected with the virus. Green cautions that many scientists believe proper testing will mean an effective vaccine won't be widely available for 12 to 18 months.

He quoted cancer biologist Charles Sherr, who told him, “Fast is slow, and slow is fast.”  

Contributing: Karen Weintraub 

This article originally appeared on USA TODAY: Latest on global search for coronavirus vaccine: Three candidates show early promise

The daily business briefing: May 26, 2020 .
1. U.S. biotechnology company Novavax said Monday it was starting human trials of a potential coronavirus vaccine in Australia. "Administering our vaccine in the first participants of this clinical trial is a significant achievement, bringing us one step closer toward addressing the fundamental need for a vaccine in the fight against the global COVID‑19 pandemic," Novavax CEO Stanley Erck said. The results from the first phase of the trials are expected in July, followed by a second phase of testing. Novavax is one of several drugmakers racing to develop vaccines and treatments to fight the novel coronavirus, which has affected about 5.

—   Share news in the SOC. Networks
usr: 1
This is interesting!